{"classes":[{"categories":[{"measurements":[{"comment":"Below the level of detection.","groupId":"OG000","spread":"NA","value":"NA"},{"comment":"Below the level of detection.","groupId":"OG001","spread":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"19"}],"units":"Participants"}],"title":"Cycle 1 Day 1 Pre-dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2210","value":"3520"},{"groupId":"OG001","spread":"1420","value":"2530"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"15"}],"units":"Participants"}],"title":"Cycle 1 Day 1 Before End of Infusion"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"153","value":"307"},{"groupId":"OG001","spread":"217","value":"417"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"17"}],"units":"Participants"}],"title":"Cycle 1 Day 1 Post Infusion"},{"categories":[{"measurements":[{"comment":"Below the threshold of the assay.","groupId":"OG000","spread":"NA","value":"NA"},{"comment":"Below the threshold of the assay.","groupId":"OG001","spread":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"16"}],"units":"Participants"}],"title":"Cycle 3 Day 1 Pre-dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3520","value":"4480"},{"groupId":"OG001","spread":"1690","value":"2030"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"10"}],"units":"Participants"}],"title":"Cycle 3 Day 1 Before End of Infusion"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"253","value":"357"},{"groupId":"OG001","spread":"322","value":"447"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"15"}],"units":"Participants"}],"title":"Cycle 3 Day 1 Post Infusion"}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"20"}],"units":"Participants"}],"dispersionType":"Standard Deviation","groups":[{"description":"Participants received intravenous (IV) infusion of atezolizumab and carboplatin on Day 1 of each 21-day cycle, and nab-paclitaxel on Days 1, 8, and 15 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first during induction treatment phase. Participants received IV infusion of atezolizumab during maintenance treatment phase until loss of clinical benefit.","id":"OG000","title":"Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin)"},{"description":"Participants received IV infusion of carboplatin on Day 1 and nab-paclitaxel on Days 1, 8, and 15 of each 21-day cycle for 4 or 6 cycles or until disease progression whichever occurs first during induction treatment phase. Participants will receive best supportive care during maintenance treatment phase. Switch maintenance to pemetrexed is also permitted. Participants who were consented prior to approval of protocol Version 5 will be given the option to cross over to receive atezolizumab as monotherapy until disease progression.","id":"OG001","title":"Arm B (Nab-Paclitaxel+Carboplatin Crossover)"}],"paramType":"MEAN","populationDescription":"The PK-evaluable population was defined as all participants who received any dose of atezolizumab, carboplatin, or nab-paclitaxel and who had evaluable PK samples.","reportingStatus":"POSTED","timeFrame":"Predose (same day of treatment administration), 5-10 minutes before end of nab-paclitaxel infusion, 1 hour after nab-paclitaxel infusion (infusion duration=30 minutes) on Day 1 of Cycle 1 and 3 (1 Cycle=21 days) (up to approximately 35 months)","title":"Plasma Concentrations of Nab-Paclitaxel Reported as Total Paclitaxel","type":"SECONDARY","unitOfMeasure":"ng/mL"}